Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | BMP1 | P13497 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | METAP1 | P53582 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018092 | 0.88 | CXCR4 (0.47) | CXCR4FNTAFNTBPGGT1BEPHX2 | |
| SCHEMBL6018824 | 0.88 | CXCR4 (0.47) | CXCR4FNTAFNTBPGGT1BEPHX2 | |
| SCHEMBL4076464 | 0.87 | CXCR4 (0.78) | CXCR4EPHX2BMP1METAP2METAP1 | |
| SCHEMBL6017943 | 0.87 | CXCR4 (0.67) | CXCR4FNTAFNTBPGGT1BEPHX2 | |
| SCHEMBL6656780 | 0.85 | CXCR4 (0.53) | CXCR4FNTAFNTBPGGT1B | |
| SCHEMBL6017968 | 0.84 | CXCR4 (0.44) | CXCR4FNTAFNTBPGGT1BEPHX2 | |
| SCHEMBL6019482 | 0.82 | CXCR4 (0.50) | CXCR4FNTAFNTBPGGT1BMETAP2 | |
| SCHEMBL6018396 | 0.77 | TGM2 (0.37) | CXCR4MCHR1 | |
| SCHEMBL6019255 | 0.76 | BMP1 (0.42) | CXCR4EPHX2BMP1 | |
| SCHEMBL6018172 | 0.76 | FOLH1 (0.50) | CXCR4FNTAFNTBPGGT1BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | KUREHA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1273571-A1 | NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME | Kureha Chemical Industry Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092556-A1 | Nitrogenous compounds and antiviral drugs containing the same | NSUN2, ZC3HAV1L, PNP | CXCR4 2185/4885FNTA 2279/4885FNTB 950/4885 |
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | CXCR4, CXCR1, CXCR2 | CXCR4 1/4885FNTA 3116/4885FNTB 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.